Abstract:Abstract Chronic pain affects one in five of the general population and is the third most important cause of disability-adjusted life-years globally. Unfortunately, treatment remains inadequate due to poor efficacy and tolerability. There has been a failure in translating promising preclinical drug targets into clinic use. This reflects challenges across the whole drug development pathway, from preclinical models to trial design. Nociceptors remain an attractive therapeutic target: their sensitization makes an important contribution to many chronic pain states, they are located outside the blood–brain barrier, and they are relatively specific. The past decade has seen significant advances in the techniques available to study human nociceptors, including: the use of corneal confocal microscopy and biopsy samples to observe nociceptor morphology, the culture of human nociceptors (either from surgical or post-mortem tissue or using human induced pluripotent stem cell derived nociceptors), the application of high throughput technologies such as transcriptomics, the in vitro and in vivo electrophysiological characterization through microneurography, and the correlation with pain percepts provided by quantitative sensory testing. Genome editing in human induced pluripotent stem cell-derived nociceptors enables the interrogation of the causal role of genes in the regulation of nociceptor function. Both human and rodent nociceptors are more heterogeneous at a molecular level than previously appreciated, and while we find that there are broad similarities between human and rodent nociceptors there are also important differences involving ion channel function, expression, and cellular excitability. These technological advances have emphasized the maladaptive plastic changes occurring in human nociceptors following injury that contribute to chronic pain. Studying human nociceptors has revealed new therapeutic targets for the suppression of chronic pain and enhanced repair. Cellular models of human nociceptors have enabled the screening of small molecule and gene therapy approaches on nociceptor function, and in some cases have enabled correlation with clinical outcomes. Undoubtedly, challenges remain. Many of these techniques are difficult to implement at scale, current induced pluripotent stem cell differentiation protocols do not generate the full diversity of nociceptor populations, and we still have a relatively poor understanding of inter-individual variation in nociceptors due to factors such as age, sex, or ethnicity. We hope our ability to directly investigate human nociceptors will not only aid our understanding of the fundamental neurobiology underlying acute and chronic pain but also help bridge the translational gap.

Molecular architecture of human dermal sleeping nociceptors

Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors

Studying human nociceptors: from fundamentals to clinic

The Molecular Signature of Neuropathic Pain in a Human Model System

Transcriptomic analysis and high throughput functional characterization of human induced pluripotent stem cell derived sensory neurons

Profiling Human iPSC-Derived Sensory Neurons for Analgesic Drug Screening Using a Multi-Electrode Array

Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling

Temporal Changes of Spinal Transcriptomic Profiles in Mice With Spinal Nerve Ligation.

Comparative Gene Signature of Nociceptors Innervating Mouse Molar Teeth, Cranial Meninges, and Cornea

Emergence of nociceptive functionality and opioid signaling in human induced pluripotent stem cell-derived sensory neurons

The μ-opioid receptor differentiates two distinct human nociceptive populations relevant to clinical pain

Distinct molecular and functional properties of human induced-proprioceptor and low-threshold mechanoreceptor neurons

Investigation of cellular and molecular changes linked with neuropathic pain in healthy and injured human trigeminal nerves

Nociceptor spontaneous activity is responsible for fragmenting non–rapid eye movement sleep in mouse models of neuropathic pain

Analysis of matrisome expression patterns in murine and human dorsal root ganglia

Interaction of human keratinocytes and nerve fiber terminals at the neuro-cutaneous unit

Parallel Spinal Pathways for Transmitting Reflexive and Affective Dimensions of Nocifensive Behaviors Evoked by Selective Activation of the Mas-Related G Protein-Coupled Receptor D-Positive and Transient Receptor Potential Vanilloid 1-Positive Subsets of Nociceptors

Human Spinal Organoid-on-a-Chip to Model Nociceptive Circuitry for Pain Therapeutics Discovery

Nociceptor-immune interactomes reveal insult-specific immune signatures of pain

Defining the Functional Role of NaV1.7 in Human Nociception

The nociceptive activity of peripheral sensory neurons is modulated by the neuronal membrane proteasome